Chitinase in Humans Is a Marker for Gaucher Disease. Potential for Monitoring Therapy. 850

Pediatric Research - United States
doi 10.1203/00006450-199604001-00872
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Arimoclomol as a Potential Therapy for Neuronopathic Gaucher Disease

2018English

3. Development of Pharmacological Chaperone Therapy for Neuronopathic Gaucher Disease

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2017English

Cost-Effectiveness of Enzyme Replacement Therapy for Type 1 Gaucher Disease

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Glucosylsphingosine Is a Reliable Response Biomarker in Gaucher Disease

American Journal of Hematology
Hematology
2018English

PP044 Adherence to Enzyme Replacement Therapy in Gaucher Disease

International Journal of Technology Assessment in Health Care
Health Policy
2017English

Psy97 - Cost-Effectiveness Analysis of Enzyme Replacement Therapy for Type 1 Gaucher Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Hepatocyte Growth Factor in Saliva Is a Potential Marker of Symptomatic Periodontal Disease

Journal of oral science
MedicineDentistry
2006English

Chitinase Inhibitor Allosamidin Is a Signal Molecule for Chitinase Production in Its Producing Streptomyces

Journal of Antibiotics
Drug DiscoveryPharmacology
2006English

Cathepsin D Is a Potential Serum Marker for Poor Prognosis in Glioma Patients

Cancer Research
Cancer ResearchOncology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy